Bydureon BCise (exenatide prolonged-release) approved in the EU for paediatric patients with type 2 diabetes

AstraZeneca

8 June 2022 - First once weekly GLP-1 treatment option for paediatric patients with type-2 diabetes in the EU.

AstraZeneca’s Bydureon BCise (exenatide 2 mg prolonged-release suspension in pre-filled pens for injection) has been approved for an indication extension of its marketing authorisation in the European Union, to include the treatment of type 2 diabetes in children and adolescents 10 years and above.

Read AstraZeneca press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe , Paediatrics